KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2016 - 2018)

Historic Long-Term Debt Repayments for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Q4 2018 value amounting to $8.1 million.

  • Vertex Pharmaceuticals' Long-Term Debt Repayments rose 7655.74% to $8.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $27.9 million, marking a year-over-year increase of 4858.21%. This contributed to the annual value of $27.9 million for FY2018, which is 4858.21% up from last year.
  • Vertex Pharmaceuticals' Long-Term Debt Repayments amounted to $8.1 million in Q4 2018, which was up 7655.74% from $5.7 million recorded in Q3 2018.
  • In the past 5 years, Vertex Pharmaceuticals' Long-Term Debt Repayments ranged from a high of $264.1 million in Q3 2014 and a low of -$272.9 million during Q4 2014
  • Over the past 5 years, Vertex Pharmaceuticals' median Long-Term Debt Repayments value was $4.8 million (recorded in 2017), while the average stood at $5.3 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Long-Term Debt Repayments plummeted by 1884587.91% in 2014 and then skyrocketed by 1342680.41% in 2016.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Long-Term Debt Repayments stood at -$272.9 million in 2014, then soared by 107.21% to $19.7 million in 2015, then crashed by 78.31% to $4.3 million in 2016, then increased by 7.97% to $4.6 million in 2017, then skyrocketed by 76.56% to $8.1 million in 2018.
  • Its Long-Term Debt Repayments was $8.1 million in Q4 2018, compared to $5.7 million in Q3 2018 and $4.9 million in Q2 2018.